Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

Contributed by: Business Wire

Logo

Tags

Oncology

FDA

Health

Clinical Trials

Pharmaceutical

Biotechnology

FDA's IND Approval for Bladder Cancer Program

More Like This

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients

HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

PR Newswire associated0

Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval